var data={"title":"Ranitidine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ranitidine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6898?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">see &quot;Ranitidine: Drug information&quot;</a> and <a href=\"topic.htm?path=ranitidine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ranitidine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217321\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acid Reducer [OTC];</li>\n      <li>Deprizine FusePaq;</li>\n      <li>Deprizine RapidPaq [DSC];</li>\n      <li>GoodSense Acid Reducer [OTC];</li>\n      <li>Ranitidine Acid Reducer [OTC];</li>\n      <li>Zantac;</li>\n      <li>Zantac 150 Maximum Strength [OTC];</li>\n      <li>Zantac 75 [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217322\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acid Reducer;</li>\n      <li>ACT Ranitidine;</li>\n      <li>Apo-Ranitidine;</li>\n      <li>Dom-Ranitidine;</li>\n      <li>Myl-Ranitidine;</li>\n      <li>Mylan-Ranitidine;</li>\n      <li>PHL-Ranitidine;</li>\n      <li>PMS-Ranitidine;</li>\n      <li>RAN-Ranitidine;</li>\n      <li>Ranitidine Injection, USP;</li>\n      <li>Riva-Ranitidine;</li>\n      <li>Sandoz-Ranitidine;</li>\n      <li>Teva-Ranitidine;</li>\n      <li>Zantac;</li>\n      <li>Zantac 75;</li>\n      <li>Zantac Maximum Strength Non-Prescription</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061780\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Histamine H<sub>2</sub> Antagonist</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11444951\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consider judicial use in neonatal population due to an association of H<sub>2</sub> blocker use and an increased incidence of NEC in VLBW neonates (Guillet, 2006) and a reported approximate sixfold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) in VLBW neonates receiving ranitidine (Terrin, 2011). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal reflux:</b> Limited data available: Corrected age &lt;44 weeks: Oral: 2 mg/kg/dose every 8 hours (Birch, 2009; Sutphen, 1989, Wheatley, 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>GI bleed or stress ulcer; prophylaxis:</b> Limited data available; dosing regimens variable: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &lt;37 weeks: 0.5 mg/kg/dose every 12 hours (ASHP, 1999; Kuusela, 1998); others have used 1.5 to 3 mg/kg/<b>day</b> divided every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GA &ge;37 weeks: 1.5 to 2 mg/kg/<b>day</b> in divided doses every 8 hours (Crill, 1999); others have recommended higher dosing at 1.5 mg/kg/dose every 8 hours (Kuusela, 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ECMO: 2 mg/kg/dose every 12 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion:<b> Note:</b> Reported ranges are similar to the total daily dose with intermittent IV dosing. Loading dose: 1.5 mg/kg/dose, followed by usual range of 0.04 to 0.08 mg/kg/hour infusion (1-2 mg/kg/<b>day</b>); reported range of 0.031 to 0.125 mg/kg/hour (0.75 to 3 mg/kg/<b>day</b>); in a trial of premature neonates on concurrent dexamethasone, an infusion rate of 0.0625 mg/kg/hour was shown to maintain neonatal gastric pH &gt;4; higher rates of 0.125 mg/kg/hour have been used without additional clinical benefit (Crill, 1999; Kelly, 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ECMO: Term neonates: Loading dose: 2 mg/kg/dose over 10 minutes followed by 0.083 mg/kg/hour infusion (2 mg/kg/<b>day</b>), begin infusion 24 hours after loading dose; rate of infusion was increased by 0.042 mg/kg/hour (1 mg/kg/<b>day</b>) if gastric pH fell to &lt;4 (Wells, 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061772\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">see &quot;Ranitidine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal or gastric ulcer: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &le;16 years: 4 to 8 mg/kg/day divided twice daily; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents &gt;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Duodenal ulcer: 150 mg twice daily <b>or</b> 300 mg once daily after the evening meal or at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Gastric ulcer: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants, Children, and Adolescents &le;16 years: 2 to 4 mg/kg/day once daily; maximum daily dose: 150 mg/day </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents &gt;16 years: 150 mg once daily at bedtime </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: Adolescents &gt;16 years: 50 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &le;16 years: 2 to 4 mg/kg/day divided every 6 to 8 hours; maximum dose: 50 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &gt;16 years: 50 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erosive esophagitis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &le;16 years: Oral: 5 to 10 mg/kg/day divided twice daily; maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &gt;16 years: Oral</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Treatment:</i> 150 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance:</i> 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GI bleed or stress ulcer; prophylaxis:</b> Limited data available; dosing regimens variable: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intermittent infusion: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 2 to 6 mg/kg/day divided every 8 hours (ASHP, 1999; Crill, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents: 3 to 6 mg/kg/day divided every 6 hours; maximum daily dose: 300 mg/<b>day</b> (ASHP, 1999; Crill, 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous infusion:</i> Infants, Children, and Adolescents: Initial: 0.15 to 0.5 mg/kg/dose for 1 dose, followed by infusion of 0.08 to 0.2 mg/kg/hour (2 to 5 mg/kg/day) (Kleigman, 2007; Lugo, 2001; Osteyee, 1994) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GERD: </b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &le;16 years: 5 to 10 mg/kg/day divided twice daily; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &gt;16 years: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heartburn: </b>OTC labeling: <b>Note: Do not use for more than 14 days.</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Prevention:</i> Children &ge;12 years and Adolescents: Oral: 75 to 150 mg 30 to 60 minutes before eating food or drinking beverages which cause heartburn; maximum daily dose: 2 doses/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Relief of symptoms:</i> Children &ge;12 years and Adolescents: Oral: 75 to 150 mg twice daily; maximum daily dose: 2 doses/day </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Patients not able to take oral medication: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;16 years: IV: 2 to 4 mg/kg/day divided every 6 to 8 hours; maximum dose: 50 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge; 16 years: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">I.M, IV: 50 mg every 6 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous IV infusion: 6.25 mg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions (eg, Zollinger-Ellison):</b> Adolescents &gt;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 150 mg twice daily; adjust dose or frequency as clinically indicated; doses of up to 6 g/day have been used </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Initial: 1 mg/kg/hour; measure gastric acid output at 4 hours, if &gt;10 mEq/hour or if patient is symptomatic, increase dose in increments of 0.5 mg/kg/hour; doses of up to 2.5 mg/kg/hour (or 220 mg/hour) have been used </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anaphylaxis, adjunct therapy:</b> Infants, Children, and Adolescents: IV: 1 mg/kg/dose; maximum dose: 50 mg/dose; <b>Note:</b> Should not be used as monotherapy or as first line therapy (AAAAI/ACAAI [Lieberman, 2010]; Canadian Paediatric Society [Cheng, 2011]) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Duodenal ulcer; treatment:</b> Oral: 150 mg twice daily or 300 mg once daily after the evening meal or at bedtime; maintenance: 150 mg once daily at bedtime </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pathological hypersecretory conditions: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 150 mg twice daily; adjust dose or frequency as clinically indicated; doses of up to 6 <b>g</b>/day have been used </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Continuous infusion for Zollinger-Ellison: Initial: 1 mg/kg/hour; measure gastric acid output at 4 hours, if &gt;10 mEq/hour or if patient is symptomatic, increase dose in increments of 0.5 mg/kg/hour; doses of up to 2.5 mg/kg/hour (or 220 mg/hour) have been used </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastric ulcer, benign:</b> Oral: 150 mg twice daily; maintenance: 150 mg once daily at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>GERD:</b> Oral: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erosive esophagitis; treatment:</b> Oral: 150 mg 4 times daily; maintenance: 150 mg twice daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heartburn, prevention or relief [OTC labeling]:</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention: 75 mg to 150 mg 30 to 60 minutes before eating food or drinking beverages which cause heartburn; maximum in 24 hours; do not use for more than 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Relief of symptoms: 75 mg to 150 mg twice daily; do not use for more than 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Patients not able to take oral medication: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 50 mg every 6 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Intermittent bolus or infusion: 50 mg every 6 to 8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 6.25 mg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants, Children, and Adolescents(Aronoff, 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Based on a usual dose of 2-6 mg/kg/day divided every 8-12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR 30-50 mL/minute/1.73 m<sup>2</sup>: 2 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR 10-29 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hemodialysis: 1 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Peritoneal dialysis: 1 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous renal replacement therapy: 2 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-right:2em;text-align:justify;\">Parenteral (IV): Based on a usual dose of 2-4 mg/kg/day divided every 6-24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR 30-50 mL/minute/1.73 m<sup>2</sup>: 1 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR 10-29 mL/minute/1.73 m<sup>2</sup>: 0.5 mg/kg/dose every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 0.5 mg/kg/dose every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hemodialysis: 0.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Peritoneal dialysis: 0.5 mg/kg/dose every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Continuous renal replacement therapy: 1 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;50 mL/minute: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Oral: 150 mg every 24 hours; adjust dose cautiously if needed </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IV: 50 mg every 18-24 hours; adjust dose cautiously if needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hemodialysis: Adjust dose schedule to administer dose at the end of dialysis </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however dosage adjustment unlikely necessary due to minimal hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217292\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zantac: 50 mg/2 mL (2 mL); 150 mg/6 mL (6 mL); 1000 mg/40 mL (40 mL) [contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/2 mL (2 mL); 150 mg/6 mL (6 mL); 1000 mg/40 mL (40 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Deprizine FusePaq: 22.4 mg/mL (250 mL) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Deprizine RapidPaq: 22.4 mg/mL (250 mL [DSC]) [contains sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg/mL (10 mL [DSC], 473 mL, 474 mL, 480 mL); 75 mg/5 mL (473 mL); 150 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acid Reducer: 75 mg, 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acid Reducer: 150 mg [sodium free, sugar free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Acid Reducer: 75 mg [gluten free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ranitidine Acid Reducer: 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zantac 75: 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zantac: 150 mg [DSC], 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zantac 150 Maximum Strength: 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zantac 150 Maximum Strength: 150 mg [sodium free, sugar free; contains brilliant blue fcf (fd&amp;c blue #1); mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 75 mg, 150 mg, 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217276\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25968281\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">see &quot;Ranitidine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Deprizine FusePaq is a compounding kit for the preparation of an oral suspension. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061785\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with meals and/or at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IV: Must be diluted prior to administration; may be administered IV push, intermittent IV infusion, or continuous IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Intermittent IV infusion: Preferred over IV push to decrease risk of bradycardia;  infuse over 15 to 20 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV push: Manufacturer recommends administering over a period of at least 5 minutes, not to exceed 10 mg/minute (4 mL/minute)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Continuous IV infusion: Administer at  ordered rate; titration may be necessary for some conditions. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Administer undiluted  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14473103\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b>  0.5 mg/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217313\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules, tablets: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F). Protect from light. Protect from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store intact vials between 4&deg;C and 25&deg;C (39&deg;F to 77&deg;F); excursion permitted to 30&deg;C (86&deg;F). Protect from light; do not freeze. Avoid excessive heat (brief exposure up to 40&deg;C does not affect the product). Undiluted solution is a clear, colorless to yellow color; slight darkening does not affect potency. Stable for 48 hours at room temperature when diluted for infusion in commonly used IV solutions (eg, NS, D<sub>5</sub>W, D<sub>10</sub>W, Ringer's lactate injection, sodium bicarbonate 5% injection).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension (Deprizine FusePaq): Store unused kit between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F); store reconstituted suspension between 2&deg;C and 8&deg;C (36&deg;F and 46&deg;F). The final suspension is stable for 8 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061784\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Short-term and maintenance treatment of duodenal ulcers and benign gastric ulcers, treatment of gastroesophageal reflux disease (GERD) and treatment of erosive esophagitis (All indications: FDA approved in ages &ge;1 month and adults); treatment of pathologic hypersecretory conditions and maintenance of erosive esophagitis (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relief of heartburn associated with acid indigestion and sour stomach (OTC product: FDA approved in ages &ge;12 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Treatment of intractable duodenal ulcers (FDA approved in ages &ge;1 month and adults); treatment of pathologic hypersecretory conditions in hospitalized patients (FDA approved in adults); alternative to oral ranitidine in patients unable to take oral medication (FDA approved in ages &ge;1 month and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used for stress ulcer prophylaxis, upper GI bleeding and as adjunct treatment for anaphylaxis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217382\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RaNITIdine may be confused with amantadine, riMANTAdine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zantac may be confused with Xanax, Zarontin, Zofran, ZyrTEC</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217379\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Asystole, atrioventricular block, bradycardia (with rapid IV administration), tachycardia, vasculitis, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, confusion, dizziness, depression, drowsiness, hallucination, headache, insomnia, involuntary motor activity, malaise, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, erythema multiforme, injection site pruritus (transient), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acute porphyria, increased serum prolactin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, abdominal pain, constipation, diarrhea, nausea, necrotizing enterocolitis (very low weight neonates; Guillet 2006), pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, aplastic anemia, granulocytopenia, hemolytic anemia (immune; acquired), leukopenia, pancytopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic hepatitis, hepatic failure, hepatitis, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction (eg, bronchospasm, eosinophilia, fever)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Burning sensation at injection site (transient), pain at injection site (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Acute interstitial nephritis, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Pneumonia (causal relationship not established)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217299\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ranitidine or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food, vomiting with blood, or bloody or black stools, allergic to ranitidine or other acid reducers. Do not use with other acid reducers. Do not use 150 mg tablet with kidney disease without medical advice.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for histamine H<sub>2</sub> antagonists is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217280\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Confusion: Rare cases of reversible confusion have been associated with ranitidine; usually elderly or severely ill patients, or in patients with renal or hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Elevation in ALT levels has occurred with higher doses (&ge;100 mg) or prolonged IV therapy (&ge;5 days); monitor ALT levels daily for the remainder of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vitamin B<sub>12</sub> deficiency: Prolonged treatment (&ge;2 years) may lead to vitamin B<sub>12</sub> malabsorption and subsequent vitamin B<sub>12</sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment (ranitidine undergoes hepatic metabolism).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Porphyria: Avoid use in patients with a history of acute porphyria; may precipitate attacks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Ranitidine is primarily excreted renally; dosage adjustment is recommended in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Children: Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection: Rapid administration has been associated with bradycardia (rare), usually in patients with predisposing risk factors for cardiac rhythm disorders. Do not exceed the recommended IV administration rate(s).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Syrup: May contain up to 7.5% alcohol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; OTC labeling: When used for self-medication (OTC), notify health care provider before use if any of the following are present: Frequent chest pain; frequent wheezing particularly with heartburn; nausea/vomiting; unexplained weight loss; stomach pain; heartburn longer than 3 months; heartburn with light-headedness, sweating, or dizziness; chest pain or shoulder pain with shortness of breath; sweating or pain that spreads to arms, neck, or shoulders; light-headedness. Stop use and notify health care provider if heartburn continues, worsens, or lasts longer than 14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25731599\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use of gastric acid inhibitors, including proton pump inhibitors and H<sub>2</sub> blockers, has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia in pediatric patients (Canani, 2006). A large epidemiological study has suggested an increased risk for developing pneumonia in patients receiving H<sub>2</sub> receptor antagonists; however, a causal relationship with ranitidine has not been demonstrated. A cohort analysis including over 11,000 neonates reported an association of H<sub>2</sub> blocker use and an increased incidence of NEC in VLBW neonates (Guillet, 2006). An approximate sixfold increase in mortality, NEC, and infection (ie, sepsis, pneumonia, UTI) was reported in patients receiving ranitidine in a cohort analysis of 274 VLBW neonates (Terrin, 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217367\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C19 (minor), CYP2D6 (minor), OCT2, P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217285\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12759&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Acalabrutinib.  Management: To minimize the potential for a significant interaction, separate administration of these agents by giving acalabrutinib 2 hours before ingestion of a histamine-2 receptor antagonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Atazanavir.  Management: Specific dose limitations and administration guidelines exist; consult full interaction monograph or atazanavir prescribing information.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Bosutinib.  Management: Administer histamine H2 receptor antagonists more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Histamine H2 Receptor Antagonists may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefpodoxime. Separate oral doses by at least 2 hours. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Histamine H2 Receptor Antagonists may decrease the absorption of Cefuroxime. Separate oral doses by at least 2 hours. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Histamine H2 Receptor Antagonists may decrease the absorption of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of H2-antagonists if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with H2-antagonists should be avoided in patients who are being treated with delavirdine.  The clinical significance of short-term H2-antagonist therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Dexmethylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: RaNITIdine may increase the serum concentration of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Erlotinib.  Management: Avoid H2-antagonists in patients receiving erlotinib when possible.  If concomitant treatment cannot be avoided, erlotinib should be dosed once daily, 10 hours after and at least 2 hours before H2-antagonist dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Fosamprenavir. Cimetidine may also inhibit the metabolism of the active metabolite amprenavir, making its effects on fosamprenavir/amprenavir concentrations difficult to predict. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Gefitinib.  Management: Administer gefitinib at least 6 hours before or after administration of a histamine H2-antagonist, and closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Histamine H2 Receptor Antagonists may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Itraconazole.  Management: When this combination is used, the itraconazole should be administered with a non-diet cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Histamine H2 Receptor Antagonists may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any H2-receptor antagonist.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Histamine H2 Receptor Antagonists may diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Histamine H2 Receptor Antagonists may increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Histamine H2 Receptor Antagonists may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be impaired by H2-antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Neratinib. Specifically, histamine H2 receptor antagonists may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Histamine H2 Receptor Antagonists may decrease the serum concentration of Nilotinib.  Management: The nilotinib dose should be given 10 hours after or 2 hours before the H2 receptor antagonist in order to minimize the risk of a significant interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Histamine H2 Receptor Antagonists may decrease the serum concentration of PAZOPanib.  Management: Avoid the use of histamine H2-antagonists in combination with pazopanib.  Strategies to minimize the expected interaction between these agents (eg, dose separation) have not been investigated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Histamine H2 Receptor Antagonists may decrease the serum concentration of Posaconazole.  Management: Avoid concurrent use of oral suspension with H2-antagonists whenever possible. Monitor patients closely for decreased antifungal effects if this combination is used. Delayed-release posaconazole tablets may be less likely to interact.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prasugrel: RaNITIdine may decrease serum concentrations of the active metabolite(s) of Prasugrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Procainamide: RaNITIdine may increase the serum concentration of Procainamide. Ranitidine may also increase the concentration of the active N-acetyl-procainamide (NAPA) metabolite. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Histamine H2 Receptor Antagonists may decrease the serum concentration of Rilpivirine.  Management: Administer histamine H2 receptor antagonists at least 12 hours before or 4 hours after rilpivirine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Histamine H2 Receptor Antagonists may increase the serum concentration of Risedronate. This applies specifically to delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Histamine H2 Receptor Antagonists may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Histamine H2 Receptor Antagonists may diminish the diagnostic effect of Secretin. Specifically, use of H2-Antagonists may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of histamine H2-antagonists (H2RAs) and secretin. Discontinue H2RAs at least 2 days prior to secretin administration.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: RaNITIdine may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: Histamine H2 Receptor Antagonists may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of cimetidine or other H2-antagonists, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Histamine H2 Receptor Antagonists may decrease the serum concentration of Velpatasvir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: RaNITIdine may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217316\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217288\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217302\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Ranitidine crosses the placenta (Armentano 1989). Histamine H<sub>2</sub> antagonists have been evaluated for the treatment of gastroesophageal reflux disease (GERD) as well as gastric and duodenal ulcers during pregnancy. If needed, ranitidine is the agent of choice (Cappell 2003; Richter 2003). Histamine H<sub>2</sub> antagonists may be used for aspiration prophylaxis prior to cesarean delivery (ASA 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1061779\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">AST, ALT, serum creatinine, occult blood with GI bleeding, signs/symptoms of peptic ulcer disease; when used to prevent stress-related GI bleeding, measure the intragastric pH and try to maintain pH &gt;4; when used for Zollinger-Ellison syndrome, monitor gastric acid secretion (goal: &lt;10 mEq/hour ) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217279\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitive inhibition of histamine at H<sub>2</sub>-receptors of the gastric parietal cells, which inhibits gastric acid secretion, gastric volume, and hydrogen ion concentration are reduced. Does not affect pepsin secretion, pentagastrin-stimulated intrinsic factor secretion, or serum gastrin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217298\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 50%; IM: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Minimally penetrates the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants, Children, and Adolescents: IV, Oral: 1 to 2.3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Normal renal function: ~1.4 L/kg; CrCl 25 to 35 mL/minute: 1.76 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~15% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (minor) to N-oxide, S-oxide, and N-desmethyl metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral tablets: ~50%; IM: 90% to 100%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates (receiving ECMO): IV: 6.6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants, Children, and Adolescents: IV: 1.7 to 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: Normal renal function: 2.5 to 3 hours; Elderly: 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: Normal renal function: 2 to 2.5 hours; CrCl 25 to 35 mL/minute: 4.8 hours; Elderly: 3.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 2 to 3 hours; IM: &le;15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as unchanged drug): Oral: 30%, IV: 70%; feces (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217301\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (RaNITidine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $91.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $82.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (RaNITidine HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/2 mL (2 mL): $15.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/6 mL (6 mL): $46.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zantac Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/2 mL (2 mL): $19.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg/6 mL (6 mL): $59.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/40 mL (40 mL): $318.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Deprizine FusePaq Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22.4 mg/mL (250 mL): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (RaNITidine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/mL (473 mL): $350.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (RaNITidine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (30): $6.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $95.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $87.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zantac 150 Maximum Strength Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (50): $16.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zantac 75 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (30): $8.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zantac Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $394.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F217304\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acicard (TW);</li>\n      <li>Acidex (AR);</li>\n      <li>Aciflux (CL);</li>\n      <li>Aciloc (BF, BJ, CI, CZ, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TW, TZ, UG, VN, ZM, ZW);</li>\n      <li>Acloral (MX);</li>\n      <li>Acran (ID);</li>\n      <li>Aldin (IN);</li>\n      <li>Alquen (ES);</li>\n      <li>Anistal (DO, GT, HN, NI, SV);</li>\n      <li>Antac (BD);</li>\n      <li>Antagonin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Antak (BR);</li>\n      <li>Apo-Ranitidine (NZ);</li>\n      <li>Ardoral (ES);</li>\n      <li>Arnetin (MY);</li>\n      <li>Artonil (SE);</li>\n      <li>Atural (PE);</li>\n      <li>Ausran (AU);</li>\n      <li>Azantac (FR, MX);</li>\n      <li>Bindazac (MT);</li>\n      <li>Consec (IN);</li>\n      <li>Contracid (PH);</li>\n      <li>Curan (KR);</li>\n      <li>Danitin (PH);</li>\n      <li>Diciran (LK);</li>\n      <li>Eltidine (KR);</li>\n      <li>Ezopta (GR);</li>\n      <li>Galidrin (MX);</li>\n      <li>Gastrial (AR);</li>\n      <li>Gastridin (ID);</li>\n      <li>Gastril (MY);</li>\n      <li>Gastrone (PH);</li>\n      <li>Gastrosedol (AR);</li>\n      <li>Gertac (IE);</li>\n      <li>Hexal Ranitic (AU);</li>\n      <li>Hexer (ID);</li>\n      <li>Histac (BF, BH, BJ, CI, ET, GH, GM, GN, HU, IN, JO, KE, KW, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);</li>\n      <li>Histak (UA, ZA);</li>\n      <li>Huma-Ranidine (HU);</li>\n      <li>Hyzan (HK, MY);</li>\n      <li>Iqfadina (MX);</li>\n      <li>Junizac (DE);</li>\n      <li>Locid (KR);</li>\n      <li>Lumeran (HK);</li>\n      <li>Lydin (IN);</li>\n      <li>Nadine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Neoceptin-R (SG);</li>\n      <li>Nipodur (MT);</li>\n      <li>Nitidin (PY);</li>\n      <li>Pepiture (LK);</li>\n      <li>Peptoran (HR);</li>\n      <li>Ponaltin (KR);</li>\n      <li>Ptinolin (GR);</li>\n      <li>Pylorid (HR, HU, LU, PH);</li>\n      <li>R-Loc (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Radinat (EC);</li>\n      <li>Ranacid (BH, JO, KW, LB, SA);</li>\n      <li>Randin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Rani (BD);</li>\n      <li>Rani 2 (AU);</li>\n      <li>Ranial (IN);</li>\n      <li>Raniben (IT);</li>\n      <li>Raniberl (CZ, LV);</li>\n      <li>Ranicux (DE);</li>\n      <li>Ranidil (IT);</li>\n      <li>Ranidin (BD, ES);</li>\n      <li>Ranidine (TH);</li>\n      <li>Ranigast (LV);</li>\n      <li>Ranimex (FI);</li>\n      <li>Ranin (ID, TH);</li>\n      <li>Ranione (KR);</li>\n      <li>Ranipin (VN);</li>\n      <li>Raniplex (FR);</li>\n      <li>Ranisan (AE, BH, CY, CZ, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Ranisen (MX);</li>\n      <li>Ranitab (EC);</li>\n      <li>Ranital (CZ, HR);</li>\n      <li>Ranitic (IE, LU);</li>\n      <li>Ranitidin-B (HU);</li>\n      <li>Ranitin-150 (ET, ZW);</li>\n      <li>Ranix (HR);</li>\n      <li>Ranopine (IE);</li>\n      <li>Ranoxyl Heartburn Relief (AU);</li>\n      <li>Ranpex (BD);</li>\n      <li>Rantac (AE, BH, CY, EG, IN, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Rantacid (FI);</li>\n      <li>Rantag (AE, QA, SA);</li>\n      <li>Rantak (UA);</li>\n      <li>Rantin (ID);</li>\n      <li>Ratic (HK, TH);</li>\n      <li>Ratinal (ID);</li>\n      <li>Raxide (PH);</li>\n      <li>Ribotine (KR);</li>\n      <li>RND (TW);</li>\n      <li>Rolan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Rynyt (UA);</li>\n      <li>Sostril (DE);</li>\n      <li>Tanidina (ES);</li>\n      <li>Taural (AR, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Tyran (ID);</li>\n      <li>Ulcaid (AU, ZA);</li>\n      <li>Ulceran (HU, PE, ZW);</li>\n      <li>Ulceranin (ID);</li>\n      <li>Ulcex (IT);</li>\n      <li>Ulcin (PH);</li>\n      <li>Ulcinorm (VN);</li>\n      <li>Ulciran (PY);</li>\n      <li>Ulcodin (HR);</li>\n      <li>Ulcosan (CZ);</li>\n      <li>Ulsal (AT);</li>\n      <li>Ulticer (HK);</li>\n      <li>Ultran (PH);</li>\n      <li>Umaren (HU);</li>\n      <li>Verlost (GR);</li>\n      <li>Vesyca (SG);</li>\n      <li>Vizerul (AR);</li>\n      <li>Weichilin (TW);</li>\n      <li>Weidos (TW);</li>\n      <li>Wontac (ET);</li>\n      <li>X'Tac (MY);</li>\n      <li>Xanidine (SG, TH);</li>\n      <li>Xanomel (HU);</li>\n      <li>Xantid (BD);</li>\n      <li>Xeradin (ID);</li>\n      <li>Zantac (AE, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CN, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KR, KW, LB, LK, LR, LT, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SI, SL, SN, SR, SV, SY, TN, TR, TT, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Zantadin (ID);</li>\n      <li>Zantic (CH, DE);</li>\n      <li>Zendhin (MY);</li>\n      <li>Zerdin (PH);</li>\n      <li>Zinetac (IN);</li>\n      <li>Zydac (AE, QA);</li>\n      <li>Zylium (BR);</li>\n      <li>Zynol (ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. <i>Anesthesiology</i>. 2007;106(4):843-863.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/17413923/pubmed\" target=\"_blank\" id=\"17413923\">17413923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Armentano G, Bracco PL, Di Silverio C. Ranitidine in the treatment of reflux oesophagitis in pregnancy. <i>Clin Exp Obstet Gynecol</i>. 1989;16(4):130-133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/2627742/pubmed\" target=\"_blank\" id=\"2627742\">2627742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP Therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. <i>Am J Health Syst Pharm</i>. 1999;56(4):347-379.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/10690219/pubmed\" target=\"_blank\" id=\"10690219\">10690219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Birch JL and Newell SJ, &quot;Gastrooesophageal Reflux Disease in Preterm Infants: Current Management and Diagnostic Dilemmas,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2009, 94(5):F379-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/19307225/pubmed\" target=\"_blank\" id=\"19307225\">19307225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, Rothstein FC, Kaplan BS, et al, &ldquo;Pharmacokinetic Determination of Ranitidine Pharmacodynamics in Pediatric Ulcer Disease,&rdquo; <i>J Pediatr</i>, 1985, 107(2):301-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/4020560/pubmed\" target=\"_blank\" id=\"4020560\">4020560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canani RB, Cirillo P, Roggero P, et al, &quot;Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,&quot; <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/16651285/pubmed\" target=\"_blank\" id=\"16651285\">16651285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cappell MS. Gastric and duodenal ulcers during pregnancy. <i>Gastroenterol Clin North Am</i>. 2003;32(1):263-308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/12635419/pubmed\" target=\"_blank\" id=\"12635419\">12635419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheng A. Emergency treatment of anaphylaxis in infants and children. <i>Paediatr Child Health</i>. 2011;16(1):35-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/22211074/pubmed\" target=\"_blank\" id=\"22211074\">22211074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crill CM and Hak EB, &quot;Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients,&quot; <i>Pharmacotherapy</i>, 1999, 19(2):162-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/10030767/pubmed\" target=\"_blank\" id=\"10030767\">10030767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eddleston JM, Booker PD, and Green JR, &ldquo;Use of Ranitidine in Children Undergoing Cardiopulmonary Bypass,&rdquo; <i>Crit Care Med</i>, 1989, 17(1):26-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/ 2909317 /pubmed\" target=\"_blank\" id=\" 2909317 \"> 2909317 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fontana M, Massironi E, Rossi A, et al, &ldquo;Ranitidine Pharmacokinetics in Newborn Infants,&rdquo; <i>Arch Dis Child</i>, 1993, 68(5 Spec No):602-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/8323366/pubmed\" target=\"_blank\" id=\"8323366\">8323366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guillet R, Stoll BJ, Cotten CM, et al, &quot;Association of H2-Blocker Therapy and Higher Incidence of Necrotizing Enterocolitis in Very Low Birth Weight Infants,&quot; <i>Pediatrics</i>, 2006, 117(2):137-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/16390920/pubmed\" target=\"_blank\" id=\"16390920\">16390920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, McConnell RF Jr, Trang JM, Kluza RB. Appearance of ranitidine in breast milk following multiple dosing. <i>Clin Pharm</i>. 1985;4(3):322-324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/4039999/pubmed\" target=\"_blank\" id=\"4039999\">4039999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly EJ, Chatfield SL, Brownlee KG, et al, &quot;The Effect of Intravenous Ranitidine on the Intragastric pH of Preterm Infants Receiving Dexamethasone,&quot; <i>Arch Dis Child</i>, 1993, 69(1 Spec No):37-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/8346951/pubmed\" target=\"_blank\" id=\"8346951\">8346951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuusela AL, &quot;Long-Term Gastric pH Monitoring for Determining Optimal Dose of Ranitidine for Critically Ill Preterm and Term Neonates,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 1998, 78(2):F151-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/9577289/pubmed\" target=\"_blank\" id=\"9577289\">9577289</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberman P1, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. <i>J Allergy Clin Immunol</i>. 2010;126(3):477-480.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/20692689/pubmed\" target=\"_blank\" id=\"20692689\">20692689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopez-Herce J, Albajara L, Codoceo R, et al, &ldquo;Ranitidine Prophylaxis in Acute Gastric Mucosal Damage in Critically Ill Pediatric Patients,&rdquo; <i>Crit Care Med</i>, 1988, 16(6):591-93.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RA, Harrison AM, Cash J, Sweeley J, Vernon DD. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. <i>Crit Care Med</i>. 2001;29(4):759-764.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/11373465/pubmed\" target=\"_blank\" id=\"11373465\">11373465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osteyee JL, Banner W Jr. Effects of two dosing regimens of intravenous ranitidine on gastric pH in critically ill children. <i>Am J Crit Care</i>. 1994;3(4):267-272.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/7920954/pubmed\" target=\"_blank\" id=\"7920954\">7920954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richter JE, &ldquo;Gastroesophageal Reflux Disease During Pregnancy,&rdquo; <i>Gastroenterol Clin North Am</i>, 2003, 32(1):235-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/12635418/pubmed\" target=\"_blank\" id=\"12635418\">12635418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riley AJ, Crowley P, Harrison C. Transfer of ranitidine to biological fluids: milk and semen. In: Misiewicz JJ, Wormsley KG, eds. The clinical use of ranitidine. Oxford: Medicine Publishing Foundation, 1982:78-81. As reported by LACTMED: <a href=\"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+384\" target=\"_blank\">http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@term+@DOCNO+384</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts CJ, &ldquo;Clinical Pharmacokinetics of Ranitidine,&rdquo; <i>Clin Pharmacokinet</i>, 1984, 9(3):211-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/6329583 /pubmed\" target=\"_blank\" id=\"6329583 \">6329583 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sutphen JL and Dillard VL, &quot;Effect of Ranitidine on Twenty-Four-Hour Gastric Acidity in Infants,&quot; <i>J Pediatr</i>, 1989, 114(3):472-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/2921693/pubmed\" target=\"_blank\" id=\"2921693\">2921693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terrin G, Passariello A, De Curtis M, et al, &quot;Ranitidine Is Associated With Infections, Necrotizing Enterocolitis, and Fatal Outcome in Newborns,&quot; <i>Pediatrics</i>, 2012, 129(1):40-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/22157140/pubmed\" target=\"_blank\" id=\"22157140\">22157140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells TG, Heulitt MJ, Taylor BJ, et al, &quot;Pharmacokinetics and Pharmacodynamics of Ranitidine in Neonates Treated With Extracorporeal Membrane Oxygenation,&quot; <i>J Clin Pharmacol</i>, 1998, 38(5):402-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/9602950/pubmed\" target=\"_blank\" id=\"9602950\">9602950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheatley E and Kennedy KA, &quot;Cross-Over Trial of Treatment for Bradycardia Attributed to Gastroesophageal Reflux in Preterm Infants,&quot; <i>J Pediatr</i>, 2009, 155(4):516-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranitidine-pediatric-drug-information/abstract-text/19540518/pubmed\" target=\"_blank\" id=\"19540518\">19540518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zantac (ranitidine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; Juney 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12759 Version 248.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F217321\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F217322\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1061780\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11444951\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1061772\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F217292\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F217276\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25968281\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1061785\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14473103\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F217313\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1061784\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F217382\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F217379\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F217299\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F217280\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25731599\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F217367\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F217285\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F217316\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F217288\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F217302\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1061779\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F217279\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F217298\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F217301\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F217304\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12759|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ranitidine-drug-information\" class=\"drug drug_general\">Ranitidine: Drug information</a></li><li><a href=\"topic.htm?path=ranitidine-patient-drug-information\" class=\"drug drug_patient\">Ranitidine: Patient drug information</a></li></ul></div></div>","javascript":null}